Contents

Preface xv
Contributors xvii

CHAPTER

1
Introduction to Clinical Pharmacology
ARTHUR J. ATKINSON, JR.

Background 1
Optimizing Use of Existing Medicines 1
Evaluation and Development of Medicines 2

Pharmacokinetics 4
Concept of Clearance 4
Clinical Assessment of Renal Function 5
Dose-Related Toxicity Often Occurs When Impaired Renal Function is Unrecognized 5

PART

I
PHARMACOKINETICS

CHAPTER

2
Clinical Pharmacokinetics
ARTHUR J. ATKINSON, JR.

The Target Concentration Strategy 11
Monitoring Serum Concentrations of Digoxin as an Example 11
General Indications for Drug Concentration Monitoring 13

Concepts Underlying Clinical Pharmacokinetics 13
Initiation of Drug Therapy (Concept of Apparent Distribution Volume) 14
Continuation of Drug Therapy (Concepts of Elimination Half-Life and Clearance) 15
Drugs Not Eliminated by First-Order Kinetics 17
Mathematical Basis of Clinical Pharmacokinetics 18
First-Order Elimination Kinetics 18
Concept of Elimination Half-Life 19
Relationship of \( k \) to Elimination Clearance 19
Cumulation Factor 19
Plateau Principle 20
Application of Laplace Transforms to Pharmacokinetics 21

CHAPTER

3
Compartmental Analysis of Drug Distribution
ARTHUR J. ATKINSON, JR.

Physiological Significance of Drug Distribution Volumes 25
Physiological Basis of Multicompartmental Models of Drug Distribution 27
Basis of Multicompartmental Structure 27
Mechanisms of Transcapillary Exchange 28
Clinical Consequences of Different Drug Distribution Patterns 30
Analysis of Experimental Data 31
Derivation of Equations for a Two-Compartment Model 31
Calculation of Rate Constants and Compartment Volumes from Data 34
Different Estimates of Apparent Volume of Distribution 34

CHAPTER

4

Drug Absorption and Bioavailability
ARTHUR J. ATKINSON, JR.

Drug Absorption 37
Bioavailability 40
Absolute Bioavailability 41
Relative Bioavailability 42
In Vitro Prediction of Bioavailability 43
Kinetics of Drug Absorption after Oral Administration 44
Time to Peak Level 46
Value of Peak Level 46
Use of Convolution/Deconvolution to Assess in Vitro-in Vivo Correlations 47

CHAPTER

5

Effects of Renal Disease on Pharmacokinetics
ARTHUR J. ATKINSON, JR. AND MARCUS M. REIDENBERG

Effects of Renal Disease on Drug Elimination 52
Mechanisms of Renal Handling of Drugs 53
Effects of Impaired Renal Function on Nonrenal Metabolism 54

Effects of Renal Disease on Drug Distribution 55
Plasma Protein Binding of Acidic Drugs 55
Plasma Protein Binding of Basic and Neutral Drugs 56
Tissue Binding of Drugs 56
Effects of Renal Disease on Drug Absorption 56

CHAPTER

6

Pharmacokinetics in Patients Requiring Renal Replacement Therapy
ARTHUR J. ATKINSON, JR. AND GREGORY M. SUSLA

Kinetics Of Intermittent Hemodialysis 59
Solute Transfer across Dialyzing Membranes 59
Calculation of Dialysis Clearance 61
Patient Factors Affecting Hemodialysis of Drugs 62

CHAPTER

7

Effect of Liver Disease on Pharmacokinetics
GREGORY M. SUSLA AND ARTHUR J. ATKINSON, JR.

Hepatic Elimination of Drugs 73
Restrictively Metabolized Drugs (ER < 0.3) 74
Drugs with an Intermediate Extraction Ratio (0.3 < ER < 0.7) 75
Nonrestrictively Metabolized Drugs (ER > 0.70) 75
Biliary Excretion of Drugs 75

Effects of Liver Disease on Pharmacokinetics 76
Acute Hepatitis 77
Chronic Liver Disease and Cirrhosis 78
Pharmacokinetic Consequences of Liver Cirrhosis 79

Use of Therapeutic Drugs in Patients with Liver Disease 80
Effects of Liver Disease on the Hepatic Elimination of Drugs 80
Effects of Liver Disease on the Renal Elimination of Drugs 82
Effects of Liver Disease on Patient Response 83
Modification of Drug Therapy in Patients with Liver Disease 84

CHAPTER

8

Noncompartmental versus Compartmental Approaches to Pharmacokinetic Analysis
DAVID M. FOSTER

Introduction 89
Kinetics, Pharmacokinetics, and Pharmacokinetic Parameters 90
Kinetics and the Link to Mathematics 90
Pharmacokinetic Parameters 91
Summary of F-ddA, CYP2B6, and Cyclosporine Analyses 177

CHAPTER 13
Clinical Pharmacogenetics
DAVID A. FLOCKHART AND LEIF BERTILSSON

Introduction 179
Hierarchy of Pharmacogenetic Information 180
Identification and Selection of Outliers in a Population 181
Examples of Important Genetic Polymorphisms 183
Drug Absorption 183
Drug Distribution 183
Drug Elimination 183
Mutations That Influence Drug Receptors 190
Combined Variants in Drug Metabolism and Receptor Genes: Value of Drug Pathway Analysis 191
Conclusions and Future Directions 191

CHAPTER 14
Equilibrative and Concentrative Transport Mechanisms
PETER C. PREUSCH

Introduction 197
Mechanisms of Transport Across Biological Membranes 197
Thermodynamics of Membrane Transport 198
Passive Diffusion 199
Carrier-Mediated Transport: Facilitated Diffusion and Active Transport 201
Uptake Mechanisms Dependent on Membrane Trafficking 202
Paracellular Transport and Permeation Enhancers 204
Description of Selected Membrane Protein Transporters 204
ATP-Binding Cassette Superfamily 205
Multifacilitator Superfamily Transporters 207
Role of Transporters in Pharmacokinetics and Drug Action 209
Role of Transporters in Drug Absorption 211
Role of Transporters in Drug Distribution 211
Role of Transporters in Drug Elimination 213
Role of Transporters in Drug Interactions 213
P-gp Inhibition as an Adjunct to Treating Chemotherapy-Resistant Cancers 214
Role of Transporters in Microbial Drug Resistance 215

Pharmacogenetics and Pharmacogenomics of Transporters 215
Pharmacogenomics of Drug Transport 215
Pharmacogenetics of Drug Transport 217
Future Directions 220
Structural Biology of Membrane Transport Proteins 220
In Silico Prediction of Drug Absorption, Distribution, Metabolism, and Elimination 220

CHAPTER 15
Drug Interactions
SARAH ROBERTSON AND SCOTT PENZAK

Introduction 229
Epidemiology 229
Classifications 229
Mechanisms of Drug Interactions 230
Interactions Affecting Drug Absorption 230
Interactions Affecting Drug Distribution 231
Interactions Affecting Drug Metabolism 232
Interactions Involving Drug Transport Proteins 237
Interactions Affecting Renal Excretion 242
Prediction and Clinical Management of Drug Interactions 242
In Vitro Screening Methods 242
Genetic Variation 243
Clinical Management of Drug Interactions 243

CHAPTER 16
Biochemical Mechanisms of Drug Toxicity
ARTHUR J. ATKINSON, JR. AND SANFORD P. MARKEY

Introduction 249
Drug-Induced Methemoglobinemia 249
Role of Covalent Binding in Drug Toxicity 252
Drug-Induced Liver Toxicity 253
Hepatotoxic Reactions Resulting from Covalent Binding of Reactive Metabolites 253
Immunologically Mediated Hepatotoxic Reactions 255
Mechanisms of Other Drug Toxicities 259
- Systemic Reactions Resulting from Drug Allergy 259
- Carcinogenic Reactions to Drugs 263
- Teratogenic Reactions to Drugs 266

PART

III
ASSESSMENT OF DRUG EFFECTS

CHAPTER
17
Physiological and Laboratory Markers of Drug Effect
ARTHUR J. ATKINSON, JR. AND PAUL ROLAN

Biological Markers of Drug Effect 275
Identification and Evaluation of Biomarkers 277
Uses of Biomarkers and Surrogate Endpoints 279
- Use of Serum Cholesterol as a Biomarker and Surrogate Endpoint 280
- Application of Serial Biomarker Measurements 282
Future Development of Biomarkers 283

CHAPTER
18
Dose-Effect and Concentration-Effect Analysis
ELIZABETH S. LOWE AND FRANK M. BALIS

Background 289
- Drug-Receptor Interactions 290
  - Receptor Occupation Theory 291
  - Receptor-Mediated Effects 292
- Graded Dose-Effect Relationship 292
  - Dose-Effect Parameters 293
  - Dose Effect and Site of Drug Action 294
- Quantal Dose-Effect Relationship 295
  - Therapeutic Indices 296
  - Dose Effect and Defining Optimal Dose 297
Pharmacodynamic Models 298
- Fixed-Effect Model 298
- Maximum-Effect ($E_{\text{max}}$) and Sigmoid $E_{\text{max}}$ Models 298

PART

IV
OPTIMIZING AND EVALUATING PATIENT THERAPY

CHAPTER
21
Pharmacological Differences between Men and Women
MAYLEE CHEN, JOSEPH S. BERTINO, JR., MARY J. BERG, AND ANNE N. NAFZIGER

Pharmacokinetics 325
- Absorption 326
CHAPTER 22

Drug Therapy in Pregnant and Nursing Women
CATHERINE S. STIKA AND MARILYNN C. FREDERIKSEN

Pregnancy Physiology and its Effects On Pharmacokinetics 340
Gastrointestinal Changes 340
Cardiovascular Effects 340
Blood Composition Changes 341
Renal Changes 342
Hepatic Drug-Metabolizing Changes 342
Peripartum Changes 344
Postpartum Changes 344
Pharmacokinetic Studies During Pregnancy 344
Results of Selected Pharmacokinetic Studies in Pregnant Women 344
Guidelines for the Conduct of Drug Studies in Pregnant Women 347
Placental Transfer of Drugs 348
Teratogenesis 349
Principles of Teratology 350
Measures to Minimize Teratogenic Risk 351
Drug Therapy in Nursing Mothers 352

CHAPTER 23

Drug Therapy in Neonates and Pediatric Patients
ELIZABETH FOX AND FRANK M. BALIS

Background 359

CHAPTER 24

Drug Therapy in the Elderly
DARRELL R. ABERNETHY

Introduction 375
Pathophysiology of Aging 375
Age-Related Changes in Pharmacokinetics 377
Age-Related Changes in Renal Clearance 377
Age-Related Changes in Hepatic and Extrahepatic Drug Biotransformations 378
Age-Related Changes in Effector System Function 379
Central Nervous System 379
Autonomic Nervous System 380
Cardiovascular Function 381
Renal Function 382
Hematopoietic System and the Treatment of Cancer 383
Drug Groups for Which Age Confers Increased Risk for Toxicity 383
Conclusions 385

CHAPTER 25

Clinical Analysis of Adverse Drug Reactions
KARIM ANTON CALIS, EMIL N. SIDA WY, AND LINDA R. YOUNG

Introduction 389
Epidemiology 389
Definitions 389
Classification 390
Clinical Detection 391
Risk Factors 393
Detection Methods 395
Clinical Evaluation 395
Causality Assessment 396
Reporting Requirements 397
ADR Detection in Clinical Trials 398
Methodology 398
Limitations 399
Reporting Requirements 399
Information Sources 399

CHAPTER

26

Quality Assessment of Drug Therapy
CHARLES E. DANIELS

Introduction 403
Adverse Drug Events 403
Medication Use Process 404
Improving the Quality of Medication Use 405
Organizational Influences On Medication Use
Quality 406
Medication Policy Issues 407
Formulary Management 407
Analysis and Prevention of Medication Errors 409
Medication Use Evaluation 414
Summary 417

PART

V

DRUG DISCOVERY AND DEVELOPMENT

CHAPTER

27

Portfolio and Project Planning and Management in the Drug Discovery, Development, and Review Process
CHARLES GRUDZINSKAS

Introduction 423
What Is a Portfolio? 423

CHAPTER

28

Drug Discovery
SHANNON DECKER AND EDWARD A. SAUSVILLE

Introduction 439
Definition of Drug Targets 439
Empirical Drug Discovery 440
Rational Drug Discovery 440
Generating Diversity 443
Natural Products 443
Chemical Compound Libraries 443
Definition of Lead Structures 444
Biochemical Screens 444
Cell-Based Screens 444
Structure-Based Drug Design 445
Qualifying Leads for Transition to Early Trials 445
CHAPTER 29

Preclinical Drug Development
CHRIS H. TAKIMOTO AND MICHAEL WICK

INTRODUCTION 449
Components of Preclinical Drug Development 450
In Vitro Studies 450
Drug Supply and Formulation 451
In Vivo Studies — Efficacy Testing in Animal Models 452
In Vivo Studies — Preclinical Pharmacokinetic and Pharmacodynamic Testing 455
In Vivo Studies — Preclinical Toxicology 455
Drug Development Programs at the NCI 456
History 456
The 3-Cell-Line Prescreen and 60-Cell-Line Screen 456
NCI Drug Development Process 459
The Challenge — Molecularily Targeted Therapies and New Paradigms for Clinical Trials 459

CHAPTER 30

Animal Scale-Up
ROBERT L. DEDRICK AND ARTHUR J. ATKINSON, JR.

Introduction 463
Allometry 463
Use of Allometry to Predict Human Pharmacokinetic Parameters 465
Use of Allometry in Designing Intraperitoneal Dose Regimens 465
Physiological Pharmacokinetics 467
In Vitro-in Vivo Correlation of Hepatic Metabolism 469

CHAPTER 31

Phase I Clinical Studies
JERRY M. COLLINS

Introduction 473
Disease-Specific Considerations 473
Starting Dose and Dose Escalation 474
Modified Fibonacci Escalation Scheme 474
Pharmacologically Guided Dose Escalation 475
Interspecies Differences in Drug Metabolism 475
Active Metabolites 476
Beyond Toxicity 477

CHAPTER 32

Pharmacokinetic and Pharmacodynamic Considerations in the Development of Biotechnology Products and Large Molecules
PAMELA D. GARZONE

Introduction 479
Monoclonal Antibodies 479
Assay of Macromolecules 482
Interspecies Scaling of Macromolecules: Predictions in Humans 482
Pharmacokinetic Characteristics of Macromolecules 483
Endogenous Concentrations 483
Absorption 485
Distribution 487
Metabolism 489
Renal Excretion 490
Application of Sparse Sampling and Population Kinetic Methods 492
Pharmacodynamics 494
Models 494
Regimen Dependency 496

CHAPTER 33

Design of Clinical Development Programs
CHARLES GRUDZINSKAS

Introduction 501
Phases, Size, and Scope of Clinical Development Programs 501
Global Development 501
Clinical Drug Development Phases 502
Drug Development Time and Cost — A Changing Picture 502
Impact of Regulation on Clinical Development Programs 504
Goal and Objectives of Clinical Drug Development 505
Objective 1 — Clinical Pharmacology and Pharmacometrics 506
Objective 2 — Safety 506
Objective 3 — Activity 506
Objective 4 — Effectiveness 506
Objective 5 — Differentiation 506
Objective 6 — Preparation of a Successful NDA/BLA Submission 506
Objective 7 — Market Expansion and Postmarketing Surveillance 506

Critical Drug Development Paradigms 507
Label-Driven Question-Based Clinical Development Plan Paradigm 507
Differentiation Paradigm 507
Drug Action → Response → Outcome → Benefit Paradigm 508
Learning vs Confirming Paradigm 508
Decision-Making Paradigm 508
Fail Early/Fail Cheaply Paradigm 508

Critical Clinical Drug Development Decision Points 509
Which Disease State? 510
What Are the Differentiation Targets? 511
Is the Drug “Reasonably Safe” for FIH Trials? 512
Starting Dose for the FIH Trial 512
Have Clinical Proof of Mechanism and Proof of Concept Been Obtained? 512
Have the Dose, Dose Regimen, and Patient Population Been Characterized? 513
Will the Product Grow in the Postmarketing Environment? 513
Will the Clinical Development Program Be Adequate for Regulatory Approval? 513

Learning Contemporary Clinical Drug Development 514
Courses and Other Educational Opportunities 514
Failed Clinical Drug Development Programs as Teaching Examples 515

CHAPTER 34
Role of the FDA in Guiding Drug Development
LAWRENCE J. LESKO AND CHANDRA G. SAHAJWALLA
Why does the FDA Get Involved in Drug Development? 520
When does the FDA Get Involved in Drug Development? 520
How does the FDA Guide Drug Development? 521
What Are FDA Guidances? 523

Appendix I
Abbreviated Tables of Laplace Transforms 527

Appendix II
ARTHUR J. ATKINSON, JR.
Answers to Study Problems 529

Index 537